Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- Labs with questionably high billing for additional tests alongside COVID-19 tests warrant further scrutiny1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1